Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Design Therapeutics, Inc.DSGN · Entity 4991 | Director | August 13, 2025 | August 14, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Design Therapeutics, Inc.
Report date August 13, 2025 · Filed August 14, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Logos Global Master Fund LP | 2,655,000 |
Reported balance
After 2025-08-13 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2025-08-13 · Sale · Disposed 345,000 · Balance 2,655,000 F1: Logos GP LLC ("Fund GP") is the general partner of Logos Global Master Fund LP (the "Fund"). The Reporting Person is the Managing Member of Fund GP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy Logos Opportunities Fund II LP | 1,000,000 |
Reported balance
After 2025-08-13 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2025-08-13 · Sale · Disposed 217,627 · Balance 1,000,000 F2: Logos Global Management LP is the investment advisor of private funds, including Logos Opportunities Fund II LP ("LOF II"). Logos Opportunities GP LLC ("GP I") is the general partner of LOF II. The Reporting Person is the Managing Member of GP I. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Logos GP LLC ("Fund GP") is the general partner of Logos Global Master Fund LP (the "Fund"). The Reporting Person is the Managing Member of Fund GP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
F2: Logos Global Management LP is the investment advisor of private funds, including Logos Opportunities Fund II LP ("LOF II"). Logos Opportunities GP LLC ("GP I") is the general partner of LOF II. The Reporting Person is the Managing Member of GP I. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 13, 2025 Filed Aug 14, 2025 20:15 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | SaleCommon Stock | 217,627 | $5.25 | $1,142,541.75 |
DisclosureSEC source: 0001415889-25-021842 · form4-08142025_040805.xml · nonDerivative · entry 2 William Arsani · CIK 0001848372 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Logos Opportunities Fund II LP Disclosed balance after: 1,000,000 F2 · ownership.nature: Logos Global Management LP is the investment advisor of private funds, including Logos Opportunities Fund II LP ("LOF II"). Logos Opportunities GP LLC ("GP I") is the general partner of LOF II. The Reporting Person is the Managing Member of GP I. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 13, 2025 Filed Aug 14, 2025 20:15 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | SaleCommon Stock | 345,000 | $5.25 | $1,811,250.00 |
DisclosureSEC source: 0001415889-25-021842 · form4-08142025_040805.xml · nonDerivative · entry 1 William Arsani · CIK 0001848372 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Logos Global Master Fund LP Disclosed balance after: 2,655,000 F1 · ownership.nature: Logos GP LLC ("Fund GP") is the general partner of Logos Global Master Fund LP (the "Fund"). The Reporting Person is the Managing Member of Fund GP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:30 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | GrantStock Option (right to buy) · Derivative | 19,000 | $0.00 Strike: $4.01 | $0.00 |
DisclosureSEC source: 0001415889-25-016959 · form4-06122025_040614.xml · derivative · entry 1 William Arsani · CIK 0001848372 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2035-06-09 F1 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over 12 months following June 10, 2025 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders. Read SEC document |
| August 09, 2024 Filed Aug 12, 2024 20:30 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | SaleCommon Stock | 814,874 | $4.25 | $3,463,214.50 |
DisclosureSEC source: 0001415889-24-021086 · form4-08122024_080818.xml · nonDerivative · entry 1 William Arsani · CIK 0001848372 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Logos SPV I LP Disclosed balance after: 0 F1 · ownership.nature: Logos Global Management LP is the investment advisor of private funds, including Logos Opportunities Fund II LP ("LOF II") and Logos SPV 1 LP ("SPV 1"). Logos Opportunities GP LLC ("GP I") is the general partner of LOF II. Logos Opportunities II GP LLC ("GP II") is the general partner of SPV 1. The Reporting Person is the Managing Member of both GP I and GP II. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 21:00 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | GrantStock Option (right to buy) · Derivative | 19,000 | $0.00 Strike: $3.82 | $0.00 |
DisclosureSEC source: 0001415889-24-017241 · form4-06172024_050620.xml · derivative · entry 1 William Arsani · CIK 0001848372 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2034-06-12 F1 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over 12 months following June 13, 2024 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders. Read SEC document |
| August 29, 2023 Filed Aug 30, 2023 22:02 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | PurchaseCommon Stock | 1,960,000 | $2.44 | $4,782,400.00 |
DisclosureSEC source: 0001209191-23-047773 · doc4.xml · nonDerivative · entry 2 William Arsani · CIK 0001848372 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Logos Global Master Fund LP Disclosed balance after: 3,000,000 F3 · price: The weighted average purchase price for the transaction was $2.44. The shares were purchased at a range of prices between $2.29 and $2.50, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. F2 · ownership.nature: Logos GP LLC ("Fund GP") is the general partner of Logos Global Master Fund LP (the "Fund"). The Reporting Person is the Managing Member of Fund GP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 28, 2023 Filed Aug 30, 2023 22:02 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | PurchaseCommon Stock | 275,000 | $2.15 | $591,250.00 |
DisclosureSEC source: 0001209191-23-047773 · doc4.xml · nonDerivative · entry 1 William Arsani · CIK 0001848372 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Logos Global Master Fund LP Disclosed balance after: 1,040,000 F1 · price: The weighted average purchase price for the transaction was $2.15. The shares were purchased at a range of prices between $2.11 and $2.1677, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. F2 · ownership.nature: Logos GP LLC ("Fund GP") is the general partner of Logos Global Master Fund LP (the "Fund"). The Reporting Person is the Managing Member of Fund GP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 20:31 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $5.63 | $0.00 |
DisclosureSEC source: 0001209191-23-033782 · doc4.xml · derivative · entry 1 William Arsani · CIK 0001848372 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2033-05-30 F1 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over 12 months following May 31, 2023 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders. Read SEC document |
| June 15, 2022 Filed Jun 16, 2022 21:08 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $13.69 | $0.00 |
DisclosureSEC source: 0001209191-22-037514 · doc4.xml · derivative · entry 1 William Arsani · CIK 0001848372 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-14 F1 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over 12 months following June 15, 2022 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders. Read SEC document |
| March 21, 2022 Filed Mar 22, 2022 23:28 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | PurchaseCommon Stock | 25,000 | $18.99 | $474,680.00 |
DisclosureSEC source: 0001209191-22-020638 · doc4.xml · nonDerivative · entry 3 William Arsani · CIK 0001848372 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Logos Global Master Fund LP Disclosed balance after: 2,797,501 F2 · ownership.nature: Logos Global Management LP ("LGM") is the investment adviser of private funds, including Logos Global Master Fund LP (the "Fund"). Logos GP LLC ("Fund GP") is the general partner of the Fund. The Reporting Person is the Manager of Fund GP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 31, 2021 Filed Sep 2, 2021 21:06 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | PurchaseCommon Stock | 40,000 | $15.45 | $618,000.00 |
DisclosureSEC source: 0001209191-21-054492 · doc4.xml · nonDerivative · entry 3 William Arsani · CIK 0001848372 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Logos Global Master Fund LP Disclosed balance after: 2,772,501 F2 · price: The weighted average purchase price for the transaction was $15.45. The shares were purchased at a range of prices between $15.00 and $15.69, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. F3 · ownership.nature: Logos Global Management LP ("LGM") is the investment adviser of private funds, including Logos Global Master Fund LP (the "Fund"). Logos GP LLC ("Fund GP") is the general partner of the Fund. The Reporting Person is the Manager of Fund GP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 22:12 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | ConversionSeries B Preferred Stock · Derivative | 1,328,245 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-024224 · doc4.xml · derivative · entry 5 William Arsani · CIK 0001848372 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Logos SPV 1 LP Disclosed balance after: 0 Underlying: Common Stock · 814,874 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F1 · price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F1 · derivative.exercise_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F1 · derivative.expiration_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F2 · ownership.nature: The Reporting Person is a managing member of Logos Opportunities Fund II, L.P. and Logos SPV 1 LP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 22:12 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | ConversionSeries B Preferred Stock · Derivative | 1,984,733 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-024224 · doc4.xml · derivative · entry 4 William Arsani · CIK 0001848372 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Logos Opportunities Fund II, L.P. Disclosed balance after: 0 Underlying: Common Stock · 1,217,627 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F1 · price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F1 · derivative.exercise_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F1 · derivative.expiration_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F2 · ownership.nature: The Reporting Person is a managing member of Logos Opportunities Fund II, L.P. and Logos SPV 1 LP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 22:12 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | PurchaseCommon Stock | 700,000 | $20.00 | $14,000,000.00 |
DisclosureSEC source: 0001209191-21-024224 · doc4.xml · nonDerivative · entry 3 William Arsani · CIK 0001848372 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Logos Global Master Fund LP Disclosed balance after: 2,732,501 F3 · ownership.nature: Logos Global Management LP ("LGM") is the investment adviser of private funds, including Logos Global Master Fund LP (the "Fund"). Logos GP LLC ("Fund GP") is the general partner of the Fund. The Reporting Person is the Manager of Fund GP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 22:12 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | ConversionCommon Stock | 814,874 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-024224 · doc4.xml · nonDerivative · entry 2 William Arsani · CIK 0001848372 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Logos SPV I LP Disclosed balance after: 2,032,501 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F2 · ownership.nature: The Reporting Person is a managing member of Logos Opportunities Fund II, L.P. and Logos SPV 1 LP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 22:12 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | ConversionCommon Stock | 1,217,627 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-024224 · doc4.xml · nonDerivative · entry 1 William Arsani · CIK 0001848372 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Logos Opportunities Fund II, L.P. Disclosed balance after: 1,217,627 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F2 · ownership.nature: The Reporting Person is a managing member of Logos Opportunities Fund II, L.P. and Logos SPV 1 LP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| March 30, 2021 Filed Sep 6, 2023 21:13 UTC Amendment | Design Therapeutics, Inc. DSGN · Entity 4991 | PurchaseCommon Stock | 700,000 | $20.00 | $14,000,000.00 |
DisclosureSEC source: 0001209191-23-048441 · doc4a.xml · nonDerivative · entry 3 William Arsani · CIK 0001848372 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Logos Global Master Fund LP Disclosed balance after: 700,000 F2 · balance_after: This Form 4 is being amended to correct the amount of securities beneficially owned by the Reporting Person. This error resulted in the misreporting of the amount of securities beneficially owned by the Reporting Person on subsequent reports. F4 · ownership.nature: Logos GP LLC ("Fund GP") is the general partner of Logos Global Master Fund LP (the "Fund"). The Reporting Person is the Managing Member of Fund GP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| March 30, 2021 Filed Sep 6, 2023 21:13 UTC Amendment | Design Therapeutics, Inc. DSGN · Entity 4991 | ConversionCommon Stock | 814,874 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-048441 · doc4a.xml · nonDerivative · entry 2 William Arsani · CIK 0001848372 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Logos SPV 1 LP Disclosed balance after: 814,874 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F2 · balance_after: This Form 4 is being amended to correct the amount of securities beneficially owned by the Reporting Person. This error resulted in the misreporting of the amount of securities beneficially owned by the Reporting Person on subsequent reports. F3 · ownership.nature: Logos Global Management LP is the investment advisor of private funds, including Logos Opportunities Fund II LP ("LOF II") and Logos SPV 1 LP ("SPV 1"). Logos Opportunities GP LLC ("GP I") is the general partner of LOF II. Logos Opportunities II GP LLC ("GP II") is the general partner of SPV 1. The Reporting Person is the Managing Member of both GP I and GP II. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| March 30, 2021 Filed Sep 6, 2023 21:13 UTC Amendment | Design Therapeutics, Inc. DSGN · Entity 4991 | ConversionCommon Stock | 1,217,627 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-048441 · doc4a.xml · nonDerivative · entry 1 William Arsani · CIK 0001848372 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Logos Opportunities Fund II, L.P. Disclosed balance after: 1,217,627 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F2 · balance_after: This Form 4 is being amended to correct the amount of securities beneficially owned by the Reporting Person. This error resulted in the misreporting of the amount of securities beneficially owned by the Reporting Person on subsequent reports. F3 · ownership.nature: Logos Global Management LP is the investment advisor of private funds, including Logos Opportunities Fund II LP ("LOF II") and Logos SPV 1 LP ("SPV 1"). Logos Opportunities GP LLC ("GP I") is the general partner of LOF II. Logos Opportunities II GP LLC ("GP II") is the general partner of SPV 1. The Reporting Person is the Managing Member of both GP I and GP II. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| March 25, 2021 Filed Mar 29, 2021 21:56 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001209191-21-023466 · doc4.xml · derivative · entry 1 William Arsani · CIK 0001848372 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-03-24 F1 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over the 12 months following March 25, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.